TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27004517

Group type: EXPERIMENTAL
Intervention: CRT service improvement programme over a 1-year period
Number of subjects: 25

Group type: COMPARATOR
Intervention: No service improvement programme
Number of subjects: 25
Study: 25220298

Group type: EXPERIMENTAL
Intervention: CAD/CAM crowns
Number of subjects: 15

Group type: COMPARATOR
Intervention: Heat-pressed crowns
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study: 22623206

Group type: EXPERIMENTAL
Intervention: Treadmill training for 30 minutes, 3 days/week for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lokomat training for 30 minutes, 3 days/week for 4 weeks
Number of subjects: 30
Study: 20354057

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme (10-day duration, focused on enhancing functional capacity)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional care (including standard physiotherapy)
Number of subjects: 86
Study: 18848676

Group type: EXPERIMENTAL
Intervention: Strong African American Families program (n = 369)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Control group (n = 298)
Number of subjects: 667
Study: 15864148

Group type: EXPERIMENTAL
Intervention: Combined exercise and motivational program
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard exercise program
Number of subjects: 93
Study: 12093068

Group type: EXPERIMENTAL
Intervention: Medical Treatment (MT) for stroke prevention including antiplatelet agents, lipid-lowering drugs, diabetic and hypertension control.
Number of subjects: 219
Study: 10530683

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study: 8538490

Group type: EXPERIMENTAL
Intervention: Continuous combined therapy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 1754608

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6372981

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 6-thioguanine (6-TG)
Number of subjects: 176

Group type: COMPARATOR
Intervention: 6-thioguanine (6-TG) in nonrandomized arm for previously drug-resistant tumors
Number of subjects: 176

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) after failing 6-TG
Number of subjects: 176

Group type: COMPARATOR
Intervention: 6-thioguanine (6-TG) after failing 5-FU
Number of subjects: 176
Study: 31673419

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day + MTX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: adalimumab (ADA) 40 mg every other week + MTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: tofacitinib monotherapy
Number of subjects: 0
Study: 29807091

Group type: EXPERIMENTAL
Intervention: MR‐proADM biomarker
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: PCT biomarker
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Virtual triage algorithm with MR‐proADM cut-off of 0.80 nmol/L
Number of subjects: 313

Group type: COMPARATOR
Intervention: Outpatients treated without hospitalization
Number of subjects: 313
Study: 26967331

Group type: EXPERIMENTAL
Intervention: 6 doses albendazole
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 doses albendazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24867571

Group type: EXPERIMENTAL
Intervention: Pay-as-you-speed (PAYS) intervention with intelligent speed assistance (ISA), 30% discount off insurance premium.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group with no feedback.
Number of subjects: 250
Study: 19820030

Group type: EXPERIMENTAL
Intervention: Kisspeptin (6.4 nmol/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 10
Study: 15449641

Group type: EXPERIMENTAL
Intervention: IWQOL-Lite
Number of subjects: 1972

Group type: EXPERIMENTAL
Intervention: IWQOL-Lite with age and BMI included
Number of subjects: 1972
Study: 11289328

Group type: EXPERIMENTAL
Intervention: Ventolin CFC
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Ventolin HFA
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 9251955

Group type: EXPERIMENTAL
Intervention: Subtotal perineoplasty and interferon (IFN) injections
Number of subjects: 19

Group type: COMPARATOR
Intervention: Total perineoplasty
Number of subjects: 19
Study: 8126628

Group type: EXPERIMENTAL
Intervention: Immediate treatment with surfactant (Curosurf) at a dosage of 200 mg/kg
Number of subjects: 182
Study: 3631319

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of ascorbic acid and haloperidol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31858658

Group type: EXPERIMENTAL
Intervention: Topical cosmetic product combination (CCP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: 4% hydroquinone (HQ)
Number of subjects: 43
Study: 30981961

Group type: EXPERIMENTAL
Intervention: Biweekly tailored advice (weeks 3–11)
Number of subjects: 51

Group type: COMPARATOR
Intervention: General RRI prevention advice (baseline)
Number of subjects: 51
Study: 26715076

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy
Number of subjects: 202
Study: 24720703

Group type: EXPERIMENTAL
Intervention: ABT-450/r-ombitasvir and dasabuvir with ribavirin (group A)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Matching placebos (group B)
Number of subjects: 631
Study: 22157201

Group type: EXPERIMENTAL
Intervention: sequential TACE and RF ablation (n=69)
Number of subjects: 139

Group type: COMPARATOR
Intervention: RF ablation alone (n=70)
Number of subjects: 139
Study: 19539818

Group type: EXPERIMENTAL
Intervention: Group plus individual therapy
Number of subjects: 2380

Group type: COMPARATOR
Intervention: Individual therapy only
Number of subjects: 2380
Study: 17483363

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: ERCC1 mRNA expression
Number of subjects: 170
Study: 15531038

Group type: EXPERIMENTAL
Intervention: Intradermal immunization with recombinant hepatitis B vaccine (3 doses)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intramuscular immunization with recombinant hepatitis B vaccine (3 doses)
Number of subjects: 100
Study: 11555442

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 6 mg/kg body weight
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 9555112

Group type: EXPERIMENTAL
Intervention: Broca's aphasics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wernicke's aphasics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7892428

Group type: EXPERIMENTAL
Intervention: Alcohol cues during conditioning sessions
Number of subjects: 12
Study: 2979250

Group type: EXPERIMENTAL
Intervention: 5 mg omeprazole
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 9
Study: 29318751

Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg) plus best supportive care (BSC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 26
Study: 27101503

Group type: EXPERIMENTAL
Intervention: Error group
Number of subjects: 1600

Group type: COMPARATOR
Intervention: No-error group
Number of subjects: 1600
Study: 25600905

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 g/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Aerobic training + placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation + aerobic training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23664333

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 699

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 699
Study: 20080082

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (group A)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Tacrolimus (group B)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 68
Study: 18412728

Group type: EXPERIMENTAL
Intervention: Light-emitting diode-based optical probe (OP) in group A (n = 96)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Light-emitting diode-based optical probe (OP) followed by root surface debridement in group B (n = 80)
Number of subjects: 44
Study: 16442460

Group type: EXPERIMENTAL
Intervention: Current body image (BMI approximately 27.7)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Desired body image (BMI approximately 27.7)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Self-perception of being overweight and attempting weight-loss
Number of subjects: 185
Study: 14522788

Group type: EXPERIMENTAL
Intervention: Nonpegged hydroxyapatite porous implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spherical alloplastic nonporous implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pegged hydroxyapatite implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sclera-covered hydroxyapatite implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unwrapped porous polyethylene implants
Number of subjects: 0
Study: 11194951

Group type: EXPERIMENTAL
Intervention: Cis-platin-based chemotherapy and irradiation
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Epirubicin-based chemotherapy and irradiation
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy groups
Number of subjects: 2000
Study: 8874988

Group type: EXPERIMENTAL
Intervention: Creatine phosphate (CP) acute treatment (6 g CP intravenously)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Creatine phosphate (CP) short-term treatment (6 g CP daily for 4 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1303072

Group type: EXPERIMENTAL
Intervention: Gluconolactone 14% in solution (Nuvoderm lotion)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide lotion
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 150
Study: 3889396

Group type: EXPERIMENTAL
Intervention: Seven days of ceftriaxone therapy
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ten days of ceftriaxone therapy
Number of subjects: 79
Study: 31337003

Group type: EXPERIMENTAL
Intervention: 0.6% povidone iodine eye drops (three day-prophylactic treatment before the injection)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo (three day-prophylactic treatment)
Number of subjects: 507
Study: 29145589

Group type: EXPERIMENTAL
Intervention: 5-min treatment video (The ABCDs of Needle Pain Management)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo video
Number of subjects: 128
Study: 27350174

Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 24740633

Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 48
Study: 23036277

Group type: EXPERIMENTAL
Intervention: Immediate radiotherapy (either 50 Gy in 25 daily fractions or 40 Gy in 15 daily fractions)
Number of subjects: 707

Group type: COMPARATOR
Intervention: No radiotherapy (delayed salvage treatment)
Number of subjects: 707
Study: 19924121

Group type: EXPERIMENTAL
Intervention: 400 mg nilotinib twice daily
Number of subjects: 119

Group type: COMPARATOR
Intervention: 400 mg nilotinib once daily
Number of subjects: 119

Group type: COMPARATOR
Intervention: 800 mg nilotinib once daily
Number of subjects: 119

Group type: COMPARATOR
Intervention: nilotinib after a high-fat meal
Number of subjects: 119
Study: 17910802

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Quetiapine vs. Risperidone
Number of subjects: 382
Study: 16082604

Group type: EXPERIMENTAL
Intervention: Once-daily subcutaneous enoxaparin (1.5 mg/kg)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU bolus and 1250 IU/hour intravenous infusion)
Number of subjects: 298
Study: 12395027

Group type: EXPERIMENTAL
Intervention: Relapse prevention intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 9498940

Group type: EXPERIMENTAL
Intervention: Proventil HFA
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Ventolin
Number of subjects: 565

Group type: COMPARATOR
Intervention: HFA-134a placebo
Number of subjects: 565
Study: 8556964

Group type: EXPERIMENTAL
Intervention: Methadone take-homes
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methadone dose increases
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Extra counseling
Number of subjects: 14
Study: 2122711

Group type: EXPERIMENTAL
Intervention: High carnitine supplementation (48 mg carnitine.kg‐1.d‐1)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (without carnitine supplementation)
Number of subjects: 2
Study: 722814

Group type: EXPERIMENTAL
Intervention: Fair-fight training for 3 weeks followed by a sexual enhancement format for 3 additional weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: The opposite treatment sequence (sexual enhancement format for 3 weeks followed by fair-fight training for 3 additional weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No‐treatment control group
Number of subjects: 14
Study: 31362772

Group type: EXPERIMENTAL
Intervention: Modified gastric tube
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional gastric tube
Number of subjects: 70
Study: 28198989

Group type: EXPERIMENTAL
Intervention: Health education provided by nurses to COPD patients
Number of subjects: 0
Study: 26231455

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 23601443

Group type: EXPERIMENTAL
Intervention: Plasmakinetic enucleation of the prostate (PKEP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Transvesical open prostatectomy (OP)
Number of subjects: 83
Study: 21331557

Group type: EXPERIMENTAL
Intervention: Merino wool graduated compression stocking
Number of subjects: 20
Study: 19248860

Group type: EXPERIMENTAL
Intervention: Lunch only enhanced
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Breakfast and lunch enhanced
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no meals enhanced)
Number of subjects: 33
Study: 16766979

Group type: EXPERIMENTAL
Intervention: Continuous compartment pressure monitoring for 36 hours
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual postoperative observations (nonmonitored group)
Number of subjects: 200
Study: 15362146

Group type: EXPERIMENTAL
Intervention: High attendance group (n = 26)
Number of subjects: 44
Study: 11122893

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9052359

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8104468

Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopenthixol decanoate
Number of subjects: 0
Study: 2439826

Group type: EXPERIMENTAL
Intervention: bopindolol 1-2 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: metoprolol 100-200 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: bopindolol 1 mg daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: bopindolol 8 mg once weekly
Number of subjects: 14
Study: 3288140

Group type: COMPARATOR
Intervention: Cold blood aortic root cardioplegia (ARC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cold blood retrograde coronary sinus cardioplegia (RCSC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Postoperative ventricular function (stroke work index versus EDVI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Postoperative LV systolic function (end-systolic blood pressure versus end-systolic volume index)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Postoperative diastolic function (pulmonary capillary wedge pressure versus EDVI)
Number of subjects: 20
Study: 30582610

Group type: COMPARATOR
Intervention: Control group (timing of dressing and staples removal)
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Clusters two to five (timing of dressing and staples removal)
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) > 35 kg/m2
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Urgent cesarean delivery (CD)
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Preterm premature rupture of membranes (PPROM)
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Chorioamnionitis at delivery
Number of subjects: 920
Study: 28816944

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) at 35 Hz for 10 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonvibrated group (placebo)
Number of subjects: 20
Study: 24842589

Group type: EXPERIMENTAL
Intervention: Web‐based family problem‐solving treatment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 132
Study: 23644396

Group type: EXPERIMENTAL
Intervention: Superficial heat using a cervical moist‐heat pack (77 °C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham using a cervical moist pack (room temperature at about 24 °C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study: 21792013

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 149

Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 149
Study: 18996761

Group type: EXPERIMENTAL
Intervention: 50,000 IU of VitD weekly after RYGB
Number of subjects: 60

Group type: COMPARATOR
Intervention: No additional VitD after RYGB
Number of subjects: 60
Study: 17043071

Group type: EXPERIMENTAL
Intervention: VT-mapping group
Number of subjects: 47

Group type: COMPARATOR
Intervention: Substrate-mapping group
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 12735558

Group type: EXPERIMENTAL
Intervention: Proximal Symmetry aortic connector
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional suture technique
Number of subjects: 107
Study: 10700684

Group type: EXPERIMENTAL
Intervention: Intramuscularly administered dexamethasone acetate (IM Dex) approximately 1.7 mg/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral prednisone (PO Pred) approximately 2 mg/kg/d for 5 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intramuscularly administered dexamethasone acetate (IM Dex)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral prednisone (PO Pred)
Number of subjects: 32
Study: 9085957

Group type: COMPARATOR
Intervention: Epinephrine test dose (15 microg) administered prior to spinal anesthesia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epinephrine test dose (15 microg) administered 30 min after injection of spinal anesthesia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epinephrine test dose (15 microg) administered at regression of sensory block to T-10
Number of subjects: 12
Study: 7682388

Group type: EXPERIMENTAL
Intervention: Adjuvant M-VAC chemotherapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Total cystectomy alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Palliative M-VAC chemotherapy
Number of subjects: 49
Study: 3947233

Group type: EXPERIMENTAL
Intervention: LeVeen peritoneovenous shunt (LPVS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Denver peritoneovenous shunt (DPVS)
Number of subjects: 22
Study: 27806212

Group type: EXPERIMENTAL
Intervention: Behavioral treatments for ADHD
Number of subjects: 148
Study: 26905792

Group type: EXPERIMENTAL
Intervention: Antibiotic information application (app)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (without the app)
Number of subjects: 62
Study: 25633158

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% (DSG 1%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23763115

Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20413514

Group type: EXPERIMENTAL
Intervention: Increased moderate-to-vigorous leisure-time physical activity (LTPA)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Resistance training (median 51 times/year)
Number of subjects: 486
Study: 18834373

Group type: COMPARATOR
Intervention: Metoprolol tartrate 100 mg (Betaloc) administered orally once to subjects in CYP2D6*1/*1 group
Number of subjects: 107

Group type: COMPARATOR
Intervention: Metoprolol tartrate 100 mg (Betaloc) administered orally once to subjects in CYP2D6*1/*10 group
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate 100 mg (Betaloc) administered orally once to subjects in CYP2D6*10/*10 group
Number of subjects: 107
Study: 16626345

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopy with chest tube insertion (Group I)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Tube thoracostomy without video-assisted thoracoscopy (Group II)
Number of subjects: 70
Study: 12618639

Group type: EXPERIMENTAL
Intervention: Integrated Care model (primary health care provided along with substance abuse treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Independent Care model (medical care provided independently from substance abuse treatment)
Number of subjects: 0
Study: 9973095

Group type: EXPERIMENTAL
Intervention: Maximal androgen blockade (MAB) treatment arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoladex and flutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (bilateral orchiectomy)
Number of subjects: 0
Study: 7701173

Group type: EXPERIMENTAL
Intervention: Running therapy (twice a week for three months)
Number of subjects: 24